Selexis and TeneoBio Team Up to Advance the Development of UniAbs Targeting Cancer
Selexis SA and TeneoBio announced that they have entered into a service agreement to advance the development of a new class of biologics, Human Heavy-Chain Antibodies (UniAbs) targeting…
Read More...
Read More...
